# A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

> **NCT06220773** · PHASE3 · RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 276 (estimated)

## Conditions studied

- Essential Hypertension
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** BR1019A
- **DRUG:** BR1019B
- **DRUG:** BR1019C
- **DRUG:** BR1019A-1
- **DRUG:** BR1019B-1
- **DRUG:** BR1019C-1

## Key facts

- **NCT ID:** NCT06220773
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06220773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06220773, "A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06220773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*